![M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/63eb1e27-7427-4152-ab57-27b36074b3fc/bjh.v188.2.cover.jpg?trick=1671240612207)
M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library
![Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41556-020-0532-x/MediaObjects/41556_2020_532_Fig1_HTML.png)
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology
![Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology](https://www.thelancet.com/cms/attachment/c880e7d6-3884-4edd-a1bc-b882d7c24b3c/gr2_lrg.jpg)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology
![Guillaume CARTRON | Head of Department | MD, PhD | Centre Hospitalier Universitaire de Montpellier, Montpellier | CHU Montpellier | Département d'hématologie clinique | Research profile Guillaume CARTRON | Head of Department | MD, PhD | Centre Hospitalier Universitaire de Montpellier, Montpellier | CHU Montpellier | Département d'hématologie clinique | Research profile](https://www.researchgate.net/publication/353525278/figure/fig1/AS:1050593904820224@1627492514224/Overall-survival-in-A-the-National-Lymphocare-Study-and-B-the-independent-validation_Q320.jpg)
Guillaume CARTRON | Head of Department | MD, PhD | Centre Hospitalier Universitaire de Montpellier, Montpellier | CHU Montpellier | Département d'hématologie clinique | Research profile
![Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/1d999e19-e581-453a-a14a-6322f3d076dc/gr1.jpg)